Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.
Kara L Davis, Catherine C Yao, Jessica A O Zimmerman...
https://pubmed.ncbi.nlm.nih.gov/41671463/Actively Recruiting
Led by Princess Maxima Center for Pediatric Oncology · Updated on 2026-10-19
160
Participants Needed
124
Research Sites
156 weeks
Total Duration
Researchers are evaluating a treatment protocol with blinatumomab for infants under 1 year old diagnosed with acute lymphoblastic leukemia ALL or mixed phenotype acute leukemia that have a specific unfavorable genetic change called KMT2A-rearrangement. The study aims to improve outcomes for these infants by adding blinatumomab to standard therapy. This is a Phase 3 interventional study sponsored by the Princess Maxima Center for Pediatric Oncology. All eligible infants will receive one cycle of blinatumomab after their initial induction therapy. Medium risk patients who respond well to the first cycle may receive a second cycle of blinatumomab replacing a chemotherapy course after consolidation therapy. High risk patients or those with insufficient response will be considered for allogeneic stem cell transplantation after the first cycle. The response to blinatumomab will be measured by minimal residual disease MRD levels. During the study, participants will be monitored closely with laboratory tests and assessments including MRD evaluations. Researchers will track event-free survival over 5 years and overall survival, relapse, and adverse events for up to 8 years. The total participation can last several years to capture long-term outcomes and safety. Parents or guardians provide consent and the study offers continuous monitoring to better understand treatment effects in this vulnerable population.
CONDITIONS
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
L
Lieke van den Wildenberg
P
Peggy Scholte-Van Houtem
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Princess Maxima Center for Pediatric Oncology
Lead Sponsor
University of Milano Bicocca
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - Several months following induction and consolidation therapies
Participants receive one cycle of blinatumomab after induction therapy. Medium risk patients who respond well may receive a second cycle replacing a chemotherapy course after consolidation therapy. High risk patients or those with insufficient response may be eligible for stem cell transplantation.
Regular visits for treatment and monitoring
Duration - Up to 8 years
Participants are monitored for event-free survival, overall survival, minimal residual disease, relapse, and adverse events for up to 8 years after treatment.
Periodic follow-up visits for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kara L Davis, Catherine C Yao, Jessica A O Zimmerman...
https://pubmed.ncbi.nlm.nih.gov/41671463/Princess Maxima Center for Pediatric Oncology
Lead Sponsor
University of Milano Bicocca
Collaborating Sponsor